SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Raleigh, NC - USA - 06-13-2024: GLP-1 related drugs newspaper headlines with hand and magnifying glass
Editorial
Serena Williams Hawks GLP-1s for Ro Even as Pharmas Face Tightening Oversight
The FDA has vowed to fix a pharma ad loophole—but they’re targeting the wrong one.
September 17, 2025
 · 
3 min read
 · 
Annalee Armstrong
Miniature doctor writing prescription. Clipboard whit signature. Rx prescription form. Medical prescription pad. Vector illustration flat design style. Medical background, template. Online clinic
Gene therapy
Doctors Still Prescribing Sarepta’s DMD Gene Therapy After Safety Concerns
A new analyst survey suggests that doctors are still prescribing Sarepta’s Elevidys, even after a series of deaths in certain populations marred the gene therapy’s record.
September 16, 2025
 · 
3 min read
 · 
Annalee Armstrong
Novo Nordisk's logo on the facade of its building in Germany
Obesity
Novo’s Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial
The sub-analysis, presented at the European Association for the Study of Diabetes congress, showed improved safety data to counteract past tolerability issues.
September 16, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top
Obesity
Novo, Lilly Jostle For Market Lead in Obesity With New Regulatory Efforts
Both Novo Nordisk and Eli Lilly are eyeing regulatory advancements for their obesity blockbusters as the European Association for the Study of Diabetes’ annual conference continues this week.
September 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Blue Sanofi sign on building in Germany at night
Drug pricing
Sanofi Joins Growing Group of Pharmas Pulling Back From UK
Merck, Eli Lilly and AstraZeneca have similarly suspended or outright canceled investments in the U.K. in the past week after a sizeable increase in a mandatory levy in the region.
September 16, 2025
 · 
2 min read
 · 
Tristan Manalac
CDC approved vaccines for adults to boost the immu
Vaccines
Kennedy Names New ACIP Members as Panel Quiets COVID-19 Vaccine Developers Ahead of Meeting
Like the first batch of appointees to the CDC’s vaccine advisory committee, several of the new panelists have documented histories of vaccine and COVID-19 skepticism.
September 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Illustration of cancer cells being held in the crosshairs of a scope
Opinion
For Scalable Success in Cell Therapy, Regional Manufacturing Is the Smart Middle Path
The patient-specific nature of autologous cell therapies presents unique challenges that can best be addressed by a middle path between on-site and centralized manufacturing.
September 16, 2025
 · 
5 min read
 · 
Jane Koo
map of United States of America with medicine pills and white background
Manufacturing
Trump’s Reshoring Drive Raises Questions About Supply Resilience
Some observers see risks to becoming over-reliant on local facilities, noting the potential need for trade partners if domestic production is disrupted.
September 16, 2025
 · 
4 min read
 · 
Nick Paul Taylor
External view of Novartis' office in Massachusetts
Collaboration
Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B
Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.
September 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS